Drug General Information |
Drug ID |
D02BGA
|
Former ID |
DNC005806
|
Drug Name |
9-Methyl-8-[1,2,3]triazol-2-yl-9H-purin-6-ylamine
|
Drug Type |
Small molecular drug
|
Indication |
Discovery agent
|
Investigative |
[1]
|
Structure |
|
Download
2D MOL
3D MOL
|
Formula |
C8H8N8
|
Canonical SMILES |
CN1C2=C(C(=NC=N2)N)N=C1N3N=CC=N3
|
InChI |
1S/C8H8N8/c1-15-7-5(6(9)10-4-11-7)14-8(15)16-12-2-3-13-16/h2-4H,1H3,(H2,9,10,11)
|
InChIKey |
ZTJZVOMEMRNYKF-UHFFFAOYSA-N
|
PubChem Compound ID |
|
Target and Pathway |
Target(s) |
Adenosine A2a receptor |
Target Info |
Inhibitor |
[1]
|
Adenosine A1 receptor |
Target Info |
Inhibitor |
[1]
|
KEGG Pathway
|
Rap1 signaling pathway
|
Calcium signaling pathway
|
cAMP signaling pathway
|
Neuroactive ligand-receptor interaction
|
Vascular smooth muscle contraction
|
Parkinson's disease
|
Alcoholismhsa04022:cGMP-PKG signaling pathway
|
Sphingolipid signaling pathway
|
Morphine addiction
|
NetPath Pathway
|
TCR Signaling Pathway
|
RANKL Signaling Pathway
|
PANTHER Pathway
|
Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway
|
Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway
|
Pathway Interaction Database
|
HIF-2-alpha transcription factor network
|
PathWhiz Pathway
|
Intracellular Signalling Through Adenosine Receptor A2a and Adenosine
|
Reactome
|
NGF-independant TRKA activation
|
Adenosine P1 receptors
|
G alpha (s) signalling events
|
Surfactant metabolismR-HSA-417973:Adenosine P1 receptors
|
G alpha (i) signalling events
|
WikiPathways
|
Nucleotide GPCRs
|
Monoamine Transport
|
GPCRs, Class A Rhodopsin-like
|
NGF signalling via TRKA from the plasma membrane
|
GPCR ligand binding
|
GPCR downstream signaling
|
GPCRs, OtherWP80:Nucleotide GPCRs
|
References |
REF 1 | J Med Chem. 2005 Nov 3;48(22):6887-96.2-n-Butyl-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-6-ylamine and analogues as A2A adenosine receptor antagonists. Design, synthesis, and pharmacological characterization. |